Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Anaptysbio (ANAB) over the last 10 years, with Sep 2025 value amounting to -$18.6 million.

  • Anaptysbio's Change in Accured Expenses fell 651.75% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$105.0 million, marking a year-over-year decrease of 2327.55%. This contributed to the annual value of -$33.8 million for FY2024, which is 409.35% down from last year.
  • Per Anaptysbio's latest filing, its Change in Accured Expenses stood at -$18.6 million for Q3 2025, which was up 16.84% from -$22.3 million recorded in Q2 2025.
  • Anaptysbio's 5-year Change in Accured Expenses high stood at $8.5 million for Q1 2023, and its period low was -$40.0 million during Q4 2024.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$2.7 million (2023), whereas its average is -$8.0 million.
  • As far as peak fluctuations go, Anaptysbio's Change in Accured Expenses skyrocketed by 8,706.67% in 2023, and later slumped by 2,573.36% in 2024.
  • Quarterly analysis of 5 years shows Anaptysbio's Change in Accured Expenses stood at -$5.3 million in 2021, then soared by 190.81% to $4.8 million in 2022, then slumped by 131.00% to -$1.5 million in 2023, then crashed by 2,573.36% to -$40.0 million in 2024, then slumped by 651.75% to -$18.6 million in 2025.
  • Its Change in Accured Expenses was -$18.6 million in Q3 2025, compared to -$22.3 million in Q2 2025 and -$24.0 million in Q1 2025.